000298982 001__ 298982
000298982 005__ 20250615021019.0
000298982 0247_ $$2doi$$a10.1007/s00259-025-07075-8
000298982 0247_ $$2pmid$$apmid:39969538
000298982 0247_ $$2ISSN$$a1619-7070
000298982 0247_ $$2ISSN$$a1619-7089
000298982 0247_ $$2altmetric$$aaltmetric:174459415
000298982 037__ $$aDKFZ-2025-00402
000298982 041__ $$aEnglish
000298982 082__ $$a610
000298982 1001_ $$aMair, Maximilian J$$b0
000298982 245__ $$aExpression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma.
000298982 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2025
000298982 3367_ $$2DRIVER$$aarticle
000298982 3367_ $$2DataCite$$aOutput Types/Journal article
000298982 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1749820685_3256
000298982 3367_ $$2BibTeX$$aARTICLE
000298982 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298982 3367_ $$00$$2EndNote$$aJournal Article
000298982 500__ $$a2025 Jul;52(8):2771-2781
000298982 520__ $$aHigh-grade meningiomas have high recurrence rates and limited prognosis. Radioligand therapies are approved in extracranial malignancies, but their value in brain tumours including meningiomas is unclear, as data on target expression is scarce.CNS WHO grade 2 and 3 meningioma samples were immunohistochemically stained for somatostatin receptor 2a (SSTR2a), fibroblast activation protein (FAP), and human epidermal growth factor receptors 2/3 (HER2/HER3). Target expression was correlated with (epi-)genetic tumour subtyping by DNA methylation analysis, genetic alterations, and survival.Meningioma samples of 58 patients were included. SSTR2a expression (membranous/cytoplasmic) was observed in 43/55 (78.2%), and FAP expression in 15/58 (25.9%) evaluable samples, with HER2 and HER3 expression in one specimen each (1.7%). Membranous SSTR2a expression was strong in 18 (32.7%), intermediate in 12 (21.8%), and weak in 11 (20.0%) samples. While SSTR2a expression was more homogenous and mainly seen in regions with higher cellularity, FAP immunoreactivity was predominantly seen in tumour stroma and regions of lower cellularity. SSTR2a immunoreactivity was associated with TRAF7 wildtype status (p = 0.034). FAP expression was more frequent in meningiomas of CNS WHO grade 3 (vs. CNS WHO 2; p < 0.001), and samples with NF2 mutations (p = 0.032) or CDKN2A/B deletions (p = 0.013) compared to wildtype. FAP and SSTR2a expression (present vs. absent) were not associated with overall survival (p > 0.05).SSTR2a and FAP are expressed in high-grade meningioma samples to a variable extent, and differences across meningioma subtypes underscore the need for biomarkers to improve patient selection. Spatial heterogeneity of target expression should be considered in radioligand therapy design.
000298982 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000298982 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298982 650_7 $$2Other$$aBrain tumour
000298982 650_7 $$2Other$$aFibroblast activating protein
000298982 650_7 $$2Other$$aMeningioma
000298982 650_7 $$2Other$$aSomatostatin receptor
000298982 650_7 $$2Other$$aTheranostics
000298982 7001_ $$aHartenbach, Sabrina$$b1
000298982 7001_ $$aTomasich, Erwin$$b2
000298982 7001_ $$aMaas, Sybren L N$$b3
000298982 7001_ $$aBosch, Sarah A$$b4
000298982 7001_ $$aWidhalm, Georg$$b5
000298982 7001_ $$aEckert, Franziska$$b6
000298982 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b7$$udkfz
000298982 7001_ $$aHainfellner, Johannes A$$b8
000298982 7001_ $$aHartenbach, Markus$$b9
000298982 7001_ $$aBerghoff, Anna S$$b10
000298982 7001_ $$aPreusser, Matthias$$b11
000298982 7001_ $$00000-0003-0953-7624$$aAlbert, Nathalie L$$b12
000298982 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-025-07075-8$$n8$$p2771-2781$$tEuropean journal of nuclear medicine and molecular imaging$$v52$$x1619-7070$$y2025
000298982 909CO $$ooai:inrepo02.dkfz.de:298982$$pVDB
000298982 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000298982 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-0953-7624$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000298982 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000298982 9141_ $$y2025
000298982 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000298982 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000298982 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000298982 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000298982 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000298982 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-05
000298982 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-05
000298982 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000298982 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000298982 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
000298982 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000298982 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000298982 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000298982 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000298982 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000298982 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000298982 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x2
000298982 980__ $$ajournal
000298982 980__ $$aVDB
000298982 980__ $$aI:(DE-He78)B300-20160331
000298982 980__ $$aI:(DE-He78)HD01-20160331
000298982 980__ $$aI:(DE-He78)MU01-20160331
000298982 980__ $$aUNRESTRICTED